ArticleBritish journal of cancer2013
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03912883 (Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting), which is not on this map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting
Who cites it
56 citing papers in PubMed, 102 citations in OpenAlex.
- Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.Cancer chemotherapy and pharmacology · 2022Trial
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Prognostic Significance of PTEN Loss in Prostate Cancer: A Meta-Analysis of Gleason Grade and Clinical Outcomes.Cancers · 2025Review
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.International journal of molecular sciences · 2025Review
- DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.British journal of cancer · 2024Article
- Small cell neuroendocrine prostate cancer with adenocarcinoma components-case report and literature review.Translational andrology and urology · 2024Article
- Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- Article
- Correlations of PTEN and ERG Immunoexpression in Prostate Carcinoma and Lesions Related to Its Natural History: Clinical Perspectives.Current issues in molecular biology · 2023Article
- Characteristics of Radiopharmaceutical Uptake in Primary Tumor and Metastatic Lesions of Prostate Carcinoma: Comparison of Oligometastatic with Multimetastatic Disease.Molecular imaging and radionuclide therapy · 2023Article
- Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease.Biomedicines · 2022Review
- Prostate zones and cancer: lost in transition?Nature reviews. Urology · 2022Review
- Article
- Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.Clinical proteomics · 2020Review
- Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.International journal of cancer · 2020Article
- Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019Review
- The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Molecular Biomarkers in the Clinical Management of Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2018Review
- Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.The Prostate · 2018Article
- Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundThe natural history of prostate cancer is highly variable and difficult to predict. We report on the prognostic value of phosphatase and tensin homologue (PTEN) loss in a cohort of 675 men with conservatively managed prostate cancer diagnosed by transurethral resection of the prostate.
methodsThe PTEN status was assayed by immunohistochemistry (PTEN IHC) and fluorescent in situ hybridisation (PTEN FISH). The primary end point was death from prostate cancer.
resultsThe PTEN IHC loss was observed in 18% cases. This was significantly associated with prostate cancer death in univariate analysis (hazard ratio (HR)=3.51; 95% CI 2.60-4.73; P=3.1 × 10(-14)). It was highly predictive of prostate cancer death in the 50% of patients with a low risk score based on Gleason score, PSA, Ki-67 and extent of disease (HR=7.4; 95% CI 2.2-24.6; P=0.012) ), but had no prognostic value in the higher risk patients. The PTEN FISH loss was only weakly associated with PTEN IHC loss (κ=0.5). Both PTEN FISH loss and amplification were univariately predictive of death from prostate cancer, but this was not maintained in the multivariate analyses.
conclusionIn low-risk patients, PTEN IHC loss adds prognostic value to Gleason score, PSA, Ki-67 and extent of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.